Intrexon and Merck KGaA, Darmstadt, Germany, Announce Agreement Realizing Precigen's Vision for Full Developmental Autonomy of its CAR-T Program

Author's Avatar
Dec 20, 2018
Article's Main Image

- Merck KGaA, Darmstadt, Germany, to assign its Chimeric Antigen Receptor T-cell (CAR-T) rights to Intrexon

- Intrexon to issue Merck KGaA, Darmstadt, Germany, $150 million in Intrexon stock and a $25 million convertible note, and Intrexon to receive a $25 million cash investment

PR Newswire